• General Dermatology
  • Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Anti-Aging
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management

The Weekly Roundup: February 27-March 3

Article

ICYMI, this week we had stories about accepted NDAs and sBLAs for VP-102 and nivolumab, overviews of rare dermatologic diseases for National Rare Disease Day, antioxidants for vitiligo and mental health, and more.

POLL: What is the Most Common Type of Mole Found on Adults?

Click here to answer this week's poll.

Skin Disease Drug can Help Control Excessive Drinking

Researchers found that apremilast could reduce alcohol intake by more than half per day, on average.

Innovative Skin Biome Technology Demonstrates Effectiveness in Anti-Aging

Researchers from Crown Laboratories say new treatment has shown improvements in skin concerns such as texture, wrinkles and sun damage.

Parkinson’s Disease Linked to Increased Risk of Bullous Pemphigoid

Researchers have linked the neurodegenerative disorder to several autoimmune diseases, including the rare skin condition bullous pemphigoid.

FDA Accepts Bristol Myers Squibb’s sBLA for Nivolumab for Resected Stage IIB/C Melanoma

Nivolumab for completely resected stage IIB or IIC melanoma is also validated by the European Medicines Agency.

Verrica Pharmaceuticals' Resubmitted NDA for VP-102 Accepted by FDA

VP-102 could be the first FDA-approved treatment for molluscum contagiosum.

Blau Syndrome: A Look Into a Rare Disease Requiring Collaborative Treatment

The autoinflammatory condition is associated with mutations in the NOD2 gene and usually affects children younger than 4 years.

Discovering Dermatology Times: February 2023

Learn more about what in-depth topics were covered in the February 2023 issue of Dermatology Times®.

Looking at 5 Rare Skin Conditions

Today is Rare Disease Day. The Food and Drug Administration (FDA) defined a rare disease as a condition affecting less than 200,000 people in the United States.

What's Trending in Skin Care: February 2023

Each month, Dermatology Times® features a roundup of products trending in skin care. Find out what products are popular for the month of February.

Pointers With Portela: What to Know About Mohs Surgery

In this week’s Pointers with Dr Portela, the 208SkinDoc discusses basal cell carcinoma and Mohs surgery related to Jill Biden's most recent skin cancer diagnosis.

Vitiligo in Latin America

Latin America presents a patchwork of challenges and opportunities in vitiligo management according to a review published in the Journal of Dermatological Treatment.

Don’t Sweat It: Glycopyrronium Bromide Cream Decreases Hyperhidrosis by 66%

Following a 72-week safety and efficacy trial, researchers have determined that 1% glycopyrronium bromide cream can reduce symptoms of hyperhidrosis.

Antioxidants for Vitiligo and Mental Health

Research has begun to explore natural compounds that address the oxidative stress, autoimmunity, and altered melanogenesis that drive vitiligo pathogenesis.

How Health Care Disparities in Latin America Impact Numbers of Atopic Dermatitis

To date, publications about health care disparities in atopic dermatitis in Latin American countries are few and far between.

My Top 5 Favorite Dermatologic Devices

Innovative devices are always coming to the forefront of dermatology and contribute to patient satisfaction.

The Mainstream Patient: March 2

This week's edition of the Mainstream Patient features stories about the misunderstanding of gua sha use, how to exfoliate the face correctly according to dermatologists, the best face sunscreens of 2023, and more.

FDA Approves First-of-Its-Kind Medical Device for Second-Degree Burn Care

Convatec’s InnovaBurn device manages surgical wounds and burns, including second-degree burns.

Study Explores if Atopic Dermatitis is Only a Skin Disease

A group of dermatologists and dermatology students studied why AD may be related to certain cardiovascular diseases, neuropsychiatric diseases, autoimmune diseases, and obesity.

Researchers Optimistic About Ruxolitinib Cream as Non-Segmental Vitiligo Treatment

Following 2 phase 3 trials, the European Medicines Agency Committee for Medicinal Products for Human Use gives positive opinion on the use of ruxolitinib cream as a treatment for facial-involved non-segmental vitiligo.

Related Videos
© 2024 MJH Life Sciences

All rights reserved.